Download PDF
Am J Perinatol 2022; 39(01): 008-015
DOI: 10.1055/s-0041-1739266
SMFM Fellowship Series Article

Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes

Anna Palatnik 
1   Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin
2   Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Rachel K. Harrison
1   Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Madhuli Y. Thakkar
2   Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Rebekah J. Walker
2   Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin
3   Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Leonard E. Egede
2   Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin
3   Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
› Author Affiliations Funding The project was partially supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K24DK093699, R01DK118038, R01DK120861, PI: Egede); the National Institute for Minority Health and Health Disparities (R01MD013826, PI: Egede/Walker), and the American Diabetes Association (1-19-JDF-075, PI: Walker). Funding organizations had no role in the analysis, interpretation of data, or writing of the manuscript.
› Further Information
    Permissions and Reprints

Abstract

Objective The aim of this study was to investigate prenatal factors associated with insulin prescription as a first-line pharmacotherapy for gestational diabetes mellitus (GDM; compared with oral antidiabetic medication) after failed medical nutrition therapy.

Study Design This is a retrospective cohort study of 437 women with a singleton pregnancy and diagnosis of A2GDM (GDM requiring pharmacotherapy), delivering in a university hospital between 2015 and 2019. Maternal sociodemographic and clinical characteristics, as well as GDM-related factors, including provider type that manages GDM, were compared between women who received insulin versus oral antidiabetic medication (metformin or glyburide) as the first-line pharmacotherapy using univariable and multivariable analyses.

Results In univariable analysis, maternal age, race and ethnicity, insurance, chronic hypertension, gestational age at GDM diagnosis, glucose level after 50-g glucose loading test, and provider type were associated with insulin prescription. In multivariable analysis, after adjusting for sociodemographic and clinical maternal factors, GDM characteristics and provider type, Hispanic ethnicity (0.26, 95% confidence interval [CI]: 0.09–0.73), and lack of insurance (0.34, 95% CI: 0.13–0.89) remained associated with lower odds of insulin prescription, whereas endocrinology management of GDM (compared with obstetrics and gynecology [OBGYN]) (8.07, 95% CI: 3.27–19.90) remained associated with higher odds of insulin prescription.

Conclusion Women of Hispanic ethnicity and women with no insurance were less likely to receive insulin and more likely to receive oral antidiabetic medication for GDM pharmacotherapy, while management by endocrinology was associated with higher odds of insulin prescription.

This finding deserves more investigation to understand if differences are due to patient choice or a health disparity in the choice of pharmacologic agent for A2GDM.

Key Points

  • Insulin is recommended as a first-line pharmacotherapy for gestational diabetes.

  • Women of Hispanic ethnicity were less likely to receive insulin as first line.

  • Lack of insurance was also associated with lower odds of insulin prescription.

Keywords

gestational diabetes - insulin - oral antidiabetic medication - race and ethnicity - insurance

Note

The findings of this study were presented at the 40th annual meeting of the Society for Maternal- Fetal Medicine, Grapevine, Texas, February 5–8, 2020.




Publication History

Received: 14 January 2021

Accepted: 04 October 2021

Article published online:
10 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 2014; 103 (02) 176-185
    CrossrefPubMedGoogle Scholar
  • 2 Metzger BE, Lowe LP, Dyer AR. et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358 (19) 1991-2002
    CrossrefPubMedGoogle Scholar
  • 3 ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; Feb; 131 (02) e49-e64
    CrossrefPubMedGoogle Scholar
  • 4 Farahvar S, Walfisch A, Sheiner E. Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. Expert Rev Endocrinol Metab 2019; 14 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 5 Esakoff TF, Caughey AB, Block-Kurbisch I, Inturrisi M, Cheng YW. Perinatal outcomes in patients with gestational diabetes mellitus by race/ethnicity. J Matern Fetal Neonatal Med 2011; 24 (03) 422-426
    CrossrefPubMedGoogle Scholar
  • 6 Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol 2004; 191 (03) 969-974
    CrossrefPubMedGoogle Scholar
  • 7 Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002; 25 (10) 1862-1868
    CrossrefPubMedGoogle Scholar
  • 8 England LJ, Dietz PM, Njoroge T. et al. Preventing type 2 diabetes: public health implications for women with a history of gestational diabetes mellitus. Am J Obstet Gynecol 2009; 200 (04) 365.e1-365.e8
    CrossrefPubMedGoogle Scholar
  • 9 Landon MB, Spong CY, Thom E. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361 (14) 1339-1348
    CrossrefPubMedGoogle Scholar
  • 10 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352 (24) 2477-2486
    CrossrefPubMedGoogle Scholar
  • 11 Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med 2013; 159 (02) 123-129
    CrossrefPubMedGoogle Scholar
  • 12 Lockwood CJ, Moore T, Copel J, Silver RM, Resnik R, Greene MF. Creasy and Resnik's maternal-fetal medicine: principles and practice 8th addition. Elsevier Health Sciences 2018
    PubMedGoogle Scholar
  • 13 American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2019 . Diabetes Care 2019; 42 (Suppl. 01) S165-S172
    CrossrefPubMedGoogle Scholar
  • 14 Song R, Chen L, Chen Y. et al. Comparison of glyburide and insulin in the management of gestational diabetes: a meta-analysis. PLoS One 2017; 12 (08) e0182488
    CrossrefPubMedGoogle Scholar
  • 15 Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin Jr DK, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol 2014; 123 (06) 1177-1184
    CrossrefPubMedGoogle Scholar
  • 16 Sénat MV, Affres H, Letourneau A. et al; Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes: a randomized clinical trial. JAMA 2018; 319 (17) 1773-1780
    CrossrefPubMedGoogle Scholar
  • 17 Rowan JA, Rush EC, Plank LD. et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care 2018; 6 (01) e000456
    CrossrefPubMedGoogle Scholar
  • 18 Hanem LGE, Stridsklev S, Júlíusson PB. et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab 2018; 103 (04) 1612-1621
    CrossrefPubMedGoogle Scholar
  • 19 Coustan DR. Pharmacological management of gestational diabetes: an overview. Diabetes Care 2007; 30 (Suppl. 02) S206-S208
    CrossrefPubMedGoogle Scholar
  • 20 Malek R, Davis SN. Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. Expert Opin Drug Metab Toxicol 2016; 12 (06) 691-699
    CrossrefPubMedGoogle Scholar
  • 21 Hebert MF, Ma X, Naraharisetti SB. et al; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85 (06) 607-614
    CrossrefPubMedGoogle Scholar
  • 22 Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009; 113 (01) 193-205
    CrossrefPubMedGoogle Scholar
  • 23 Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203 (05) 457.e1-457.e9
    CrossrefPubMedGoogle Scholar
  • 24 Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350: h102
    CrossrefPubMedGoogle Scholar
  • 25 Harrison RK, Cruz M, Wong A, Davitt C, Palatnik A. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth 2020; 20 (01) 773
    CrossrefPubMedGoogle Scholar
  • 26 Donabedian A. The quality of care. How can it be assessed?. JAMA 1988; 260 (12) 1743-1748
    CrossrefPubMedGoogle Scholar
  • 27 Mahal BA, Ziehr DR, Aizer AA. et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014; 32 (08) 1285-1291
    CrossrefPubMedGoogle Scholar
  • 28 Hawks RM, McGinn AP, Bernstein PS, Tobin JN. Exploring preconception care: insurance status, race/ethnicity, and health in the pre-pregnancy period. Matern Child Health J 2018; 22 (08) 1103-1110
    CrossrefPubMedGoogle Scholar
  • 29 Daw JR, Kolenic GE, Dalton VK. et al. Racial and ethnic disparities in perinatal insurance coverage. Obstet Gynecol 2020; 135 (04) 917-924
    CrossrefPubMedGoogle Scholar
  • 30 HeathCare.gov. Health coverage if you're pregnant, plan to get pregnant, or recently gave birth. Accessed March 20, 2021 at: https://www.healthcare.gov/what-if-im-pregnant-or-plan-to-get-pregnant/
    PubMedGoogle Scholar
  • 31 Osterman MJK, Martin JA. Timing and adequacy of prenatal care in the United States, 2016. Natl Vital Stat Rep 2018; 67 (03) 1-14
    PubMedGoogle Scholar
  • 32 Daw JR, Hatfield LA, Swartz K, Sommers BD. Women in the United States experience high rates of coverage 'churn' in months before and after childbirth. Health Aff (Millwood) 2017; 36 (04) 598-606
    CrossrefPubMedGoogle Scholar
  • 33 ACOG Committee Opinion No. ACOG Committee Opinion No. 425: health care for undocumented immigrants. Obstet Gynecol 2009; 113 (01) 251-254
    CrossrefPubMedGoogle Scholar
  • 34 Capps RFM, Van Hook J, Bachmeier JD. A demographic, socioeconomic, and health coverage profile of unauthorized immigrants in the United States. Washington, DC: Migration Policy Institute; 2013. . Available at: http://www.migrationpolicy.org/sites/default/files/publications/CIRbrief-Profile-Unauthorized_1.pdf
    Google Scholar
  • 35 Reed MM, Westfall JM, Bublitz C, Battaglia C, Fickenscher A. Birth outcomes in Colorado's undocumented immigrant population. BMC Public Health 2005; 5: 100
    CrossrefPubMedGoogle Scholar
  • 36 Fuentes-Afflick E, Hessol NA, Bauer T. et al. Use of prenatal care by Hispanic women after welfare reform. Obstet Gynecol 2006; 107 (01) 151-160
    CrossrefPubMedGoogle Scholar
  • 37 Silva JK, Kaholokula JK, Ratner R, Mau M. Ethnic differences in perinatal outcome of gestational diabetes mellitus. Diabetes Care 2006; 29 (09) 2058-2063
    CrossrefPubMedGoogle Scholar
  • 38 Pu J, Zhao B, Wang EJ. et al. Racial/ethnic differences in gestational diabetes prevalence and contribution of common risk factors. Paediatr Perinat Epidemiol 2015; 29 (05) 436-443
    CrossrefPubMedGoogle Scholar
  • 39 Nguyen BT, Cheng YW, Snowden JM, Esakoff TF, Frias AE, Caughey AB. The effect of race/ethnicity on adverse perinatal outcomes among patients with gestational diabetes mellitus. Am J Obstet Gynecol 2012; 207 (04) 322.e1-322.e6
    CrossrefPubMedGoogle Scholar
  • 40 Hedderson MM, Darbinian JA, Ferrara A. Disparities in the risk of gestational diabetes by race-ethnicity and country of birth. Paediatr Perinat Epidemiol 2010; 24 (05) 441-448
    CrossrefPubMedGoogle Scholar
  • 41 Committee on Educating Health Professionals to Address the Social Determinants of Health, Board on Global Health, Institute of Medicine, National Academies of Sciences, Engineering, and Medicine. A Framework for Educating Health Professionals to Address the Social Determinants of Health. Washington, DC: The National Academies Press; 2016
    CrossrefGoogle Scholar
  • 42 Ades V, Goddard B, Pearson Ayala S, Chemouni Bach S, Wu SX. ACOG Committee Opinion No. 729: importance of social determinants of health and cultural awareness in the delivery of reproductive health care. Obstet Gynecol 2018; 131 (06) 1162-1163
    CrossrefPubMedGoogle Scholar
  • 43 ACOG Committee Opinion No. ACOG Committee Opinion No. 649: racial and ethnic disparities in obstetrics and gynecology. Obstet Gynecol 2015; 126 (06) e130-e134
    CrossrefPubMedGoogle Scholar
  • 44 Hatcher E, Whittemore R. Hispanic adults' beliefs about type 2 diabetes: clinical implications. J Am Acad Nurse Pract 2007; 19 (10) 536-545
    CrossrefPubMedGoogle Scholar
  • 45 Fernandez A, Schillinger D, Warton EM. et al. Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med 2011; 26 (02) 170-176
    CrossrefPubMedGoogle Scholar
  • 46 Palatnik A, Harrison RK, Walker RJ, Thakkar MY, Egede LE. Maternal racial and ethnic disparities in glycemic threshold for pharmacotherapy initiation for gestational diabetes. J Matern Fetal Neonatal Med 2020; Jan 13: 1-8
    PubMedGoogle Scholar
  • 47 Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44 (03) 166-206
    CrossrefPubMedGoogle Scholar
  • 48 National Health Service, England. Accessed December 10, 2020 https://improvement.nhs.uk/documents/2135/measuring-quality-care-model.pdf
    PubMedGoogle Scholar
  • 49 Arroyo-Johnson C, Mincey KD, Ackermann N, Milam L, Goodman MS, Colditz GA. Racial and ethnic heterogeneity in self-reported diabetes prevalence trends across Hispanic subgroups, national health interview survey, 1997-2012. Prev Chronic Dis 2016; 13: E10
    CrossrefPubMedGoogle Scholar
  • 50 Colby S, Ortman JM. Current Population Reports. Washington, DC: US Census Bureau; 2014. . Available at: https://www.census.gov/content/dam/Census/library/publications/2015/demo/p25-1143.pdf
    Google Scholar